ACHIEVE A RICHER LIFE
THROUGH HEARING
AND HEALTH

ACHIEVE A RICHER LIFE
THROUGH HEARING
AND HEALTH

ABOUT

ABOUT

As the global population continues to age, hearing loss has become an important social issue, as it can contribute to dementia and social isolation.
However, effective treatments are not available for many forms of hearing loss, and fundamental treatment remains difficult.
We are working to develop gene therapy for GJB2-related hereditary hearing loss, the most common form of genetic hearing loss worldwide.

About us

PIPELINE

PIPELINE

Researchers at Juntendo University have identified that one of the major causes of hereditary hearing loss is abnormalities in a molecule called gap junction in inner ear cells. Based on this discovery, they are developing new biopharmaceuticals using iPS cell technology and genetic biotechnology.
Gap Junction Therapeutics, Inc. builds on these technologies to advance the research and development of pharmaceuticals and supplements aimed at the fundamental treatment and prevention of hearing loss and other gap junction-related diseases.

Our technology